• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者体内烟酰胺的药代动力学

Nicotinamide pharmacokinetics in patients.

作者信息

Dragovic J, Kim S H, Brown S L, Kim J H

机构信息

Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI 48202, USA.

出版信息

Radiother Oncol. 1995 Sep;36(3):225-8. doi: 10.1016/0167-8140(95)01581-z.

DOI:10.1016/0167-8140(95)01581-z
PMID:8532910
Abstract

Pharmacokinetic analyses were performed on blood samples of 12 patients undergoing treatment with nicotinamide, hyperthermia and radiation therapy for a variety of recurrent/metastatic cancers. Escalating oral doses of 3, 4, 5, 6 and 10 g of nicotinamide showed a linear relationship between maximum recorded plasma concentrations and the dose in grams (correlation coefficient, r = 0.91). Maximum plasma levels were observed by 30 min in most patients ingesting up to 6 g of nicotinamide. In marked contrast, five out of six patients ingesting 10 g of nicotinamide demonstrated increasing plasma levels at least up to 3 h post-ingestion. Doses up to 6 g were well tolerated and resulted in average maximum recorded plasma levels (mean +/- 1 SEM) of 156.4 +/- 33.6 micrograms/ml. Doses of 10 g were generally not well tolerated, but a high plasma level was maintained on average for at least 4 h. Plasma concentrations of the above order have been previously associated with maximal enhancement of radiation damage in mouse tumor models. This suggests that radiosensitization can be expected to occur in human tumors following oral administration of a safe and well tolerated dose of 6 g. However, at higher doses (i.e., 10 g), the pharmacokinetics, and perhaps radiosensitization, may differ markedly.

摘要

对12例接受烟酰胺、热疗和放射治疗的复发性/转移性癌症患者的血样进行了药代动力学分析。递增口服剂量为3、4、5、6和10克烟酰胺,结果显示最大记录血浆浓度与克剂量之间呈线性关系(相关系数,r = 0.91)。大多数摄入6克以下烟酰胺的患者在30分钟时观察到血浆浓度达到最高水平。与之形成显著对比的是,摄入10克烟酰胺的6例患者中有5例在摄入后至少3小时内血浆浓度持续升高。6克以下的剂量耐受性良好,平均最大记录血浆浓度(均值±1标准误)为156.4±33.6微克/毫升。10克的剂量通常耐受性不佳,但平均至少能维持4小时的高血浆浓度。上述血浆浓度水平此前已在小鼠肿瘤模型中与辐射损伤的最大增强相关联。这表明口服6克安全且耐受性良好的剂量后,有望在人类肿瘤中产生放射增敏作用。然而,在更高剂量(即10克)时,药代动力学以及或许放射增敏作用可能会有显著差异。

相似文献

1
Nicotinamide pharmacokinetics in patients.患者体内烟酰胺的药代动力学
Radiother Oncol. 1995 Sep;36(3):225-8. doi: 10.1016/0167-8140(95)01581-z.
2
Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.烟酰胺在接受加速放疗的癌症患者中的药代动力学:欧洲癌症研究与治疗组织放疗合作组的经验
Radiother Oncol. 1998 Aug;48(2):123-33. doi: 10.1016/s0167-8140(98)00048-6.
3
Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy.烟酰胺在人和小鼠体内的药代动力学:比较评估及其对放射治疗的意义。
Radiother Oncol. 1993 May;27(2):131-9. doi: 10.1016/0167-8140(93)90133-s.
4
Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations.不同剂量烟酰胺的药代动力学以及联合使用卡波金和烟酰胺进行肿瘤放射增敏:临床考量
Br J Cancer. 1993 Dec;68(6):1115-21. doi: 10.1038/bjc.1993.490.
5
Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity.图表期间烟酰胺的给药:药代动力学、剂量递增及临床毒性。
Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1111-9. doi: 10.1016/0360-3016(95)00022-q.
6
Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing.烟酰胺作为肿瘤和正常组织中的放射增敏剂:药物剂量和给药时间的重要性。
Radiother Oncol. 1997 Nov;45(2):167-74. doi: 10.1016/s0167-8140(97)00127-8.
7
Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme.多形性胶质母细胞瘤患者中烟酰胺联合放射治疗的药代动力学及耐受性
Acta Oncol. 1994;33(8):969-73. doi: 10.3109/02841869409098465.
8
Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy.烟酰胺在正常志愿者和接受姑息性放疗患者中的药代动力学。
Acta Oncol. 1996;35(2):213-9. doi: 10.3109/02841869609098504.
9
Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring.烟酰胺在人体内的药代动力学:胃酸抑制的影响、直肠给药与口服给药的比较以及唾液用于药物监测的研究
Br J Cancer. 1996 Jul;74(1):16-21. doi: 10.1038/bjc.1996.309.
10
Impact of nicotinamide on human tumour hypoxic fraction measured using the comet assay.烟酰胺对使用彗星试验测量的人类肿瘤缺氧分数的影响。
Radiother Oncol. 1997 Nov;45(2):175-82. doi: 10.1016/s0167-8140(97)00110-2.

引用本文的文献

1
CD38-NAD(+) Axis: New Insights into Glaucoma Therapy.CD38 - NAD(+)轴:青光眼治疗的新见解
Mol Neurobiol. 2025 Jul 22. doi: 10.1007/s12035-025-05243-3.
2
Polydatin and Nicotinamide Prevent Iron Accumulation and Lipid Peroxidation in Cellular Models of Mitochondrial Diseases.虎杖苷和烟酰胺可预防线粒体疾病细胞模型中的铁积累和脂质过氧化。
Antioxidants (Basel). 2025 Feb 13;14(2):215. doi: 10.3390/antiox14020215.
3
Impact of NAD+ metabolism on ovarian aging.烟酰胺腺嘌呤二核苷酸(NAD+)代谢对卵巢衰老的影响。
Immun Ageing. 2023 Dec 2;20(1):70. doi: 10.1186/s12979-023-00398-w.
4
The Central Role of the NAD+ Molecule in the Development of Aging and the Prevention of Chronic Age-Related Diseases: Strategies for NAD+ Modulation.NAD+ 分子在衰老发展和预防慢性与年龄相关疾病中的核心作用:NAD+ 调节策略。
Int J Mol Sci. 2023 Feb 3;24(3):2959. doi: 10.3390/ijms24032959.
5
Current Uncertainties and Future Challenges Regarding NAD+ Boosting Strategies.关于NAD+增强策略的当前不确定性和未来挑战。
Antioxidants (Basel). 2022 Aug 24;11(9):1637. doi: 10.3390/antiox11091637.
6
Pharmacology and Potential Implications of Nicotinamide Adenine Dinucleotide Precursors.烟酰胺腺嘌呤二核苷酸前体的药理学及潜在影响
Aging Dis. 2021 Dec 1;12(8):1879-1897. doi: 10.14336/AD.2021.0523. eCollection 2021 Dec.
7
Healthy Lifestyle Recommendations: Do the Beneficial Effects Originate from NAD Amount at the Cellular Level?健康生活方式的建议:有益效果是否源于细胞水平的 NAD 含量?
Oxid Med Cell Longev. 2020 Dec 12;2020:8819627. doi: 10.1155/2020/8819627. eCollection 2020.
8
Implications of NAD Metabolism in the Aging Retina and Retinal Degeneration.NAD 代谢对衰老视网膜和视网膜变性的影响。
Oxid Med Cell Longev. 2020 May 9;2020:2692794. doi: 10.1155/2020/2692794. eCollection 2020.
9
What Can Go Wrong When Applying Immune Modulation Therapies to Target Persistent Bacterial Infections.将免疫调节疗法用于治疗持续性细菌感染时可能出现哪些问题。
J Cell Immunol. 2020;2(1):1-5. doi: 10.33696/immunology.2.011. Epub 2020 Jan 3.
10
Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo.组蛋白去乙酰化酶抑制剂对体内 PPN 振荡活动的差异影响。
Neuropharmacology. 2020 Mar 15;165:107922. doi: 10.1016/j.neuropharm.2019.107922. Epub 2019 Dec 23.